Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuel Hidalgo

Showing results (1-10 of 384) with videos related to

Pageof 39
Sort By:
Clinical Advances in Hematology & Oncology : H&O|March 9, 2007
The Development of rapamycin as an orphan drugManuel Hidalgo
Advances in Experimental Medicine and Biology|July 3, 2008
Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?Manuel Hidalgo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
From node to pathway blockade: lessons learned from targeting mammalian target of rapamycinManuel Hidalgo
The New England Journal of Medicine|April 30, 2010
Pancreatic cancerManuel Hidalgo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2004
New target, new drug, old paradigmManuel Hidalgo
Reproduction in Domestic Animals = Zuchthygiene|August 21, 2021
Recent advances in donkey sperm vitrificationManuel Hidalgo
Reproduction in Domestic Animals = Zuchthygiene|September 22, 2018
EditorialManuel Hidalgo
Oncology (Williston Park, N.Y.)|December 20, 2003
Erlotinib: preclinical investigationsManuel Hidalgo
Clinical Advances in Hematology & Oncology : H&O|December 5, 2017
Patient-derived tumor xenograft models in drug developmentManuel Hidalgo
Clinical Lung Cancer|January 11, 2005
Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitorsSofia Perea, Manuel Hidalgo
Pageof 39

Showing results (1-10 of 384) with videos related to

Sort By:
Pageof 39
Clinical Advances in Hematology & Oncology : H&O|March 9, 2007
The Development of rapamycin as an orphan drugManuel Hidalgo
Advances in Experimental Medicine and Biology|July 3, 2008
Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?Manuel Hidalgo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
From node to pathway blockade: lessons learned from targeting mammalian target of rapamycinManuel Hidalgo
The New England Journal of Medicine|April 30, 2010
Pancreatic cancerManuel Hidalgo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2004
New target, new drug, old paradigmManuel Hidalgo
Reproduction in Domestic Animals = Zuchthygiene|August 21, 2021
Recent advances in donkey sperm vitrificationManuel Hidalgo
Reproduction in Domestic Animals = Zuchthygiene|September 22, 2018
EditorialManuel Hidalgo
Oncology (Williston Park, N.Y.)|December 20, 2003
Erlotinib: preclinical investigationsManuel Hidalgo
Clinical Advances in Hematology & Oncology : H&O|December 5, 2017
Patient-derived tumor xenograft models in drug developmentManuel Hidalgo
Clinical Lung Cancer|January 11, 2005
Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitorsSofia Perea, Manuel Hidalgo
Pageof 39